Puzzle Financial Advice

The Johnson & Johnson COVID vaccine is an adenoviral vector vaccine, just as the AstraZeneca COVID vaccine is - and this seems to be why the J&J vaccine seems to be having similar blood clotting problems to the AstraZeneca vaccine.

​

Articles of relevance re: J&J COVID vaccine:

• https://twitter.com/EricTopol/status/1384975362203918337   22/Apr/2021

  • "The J&J vaccine Phase 3 trial is published @NEJM today At post >14 days 67% efficacy; >28 days 75% (85% vs severe/critical) and strong efficacy vs B.351 (South Africa) variant; very good safety profile"

    • If I am reading correctly, the section of the paper that Eric Topol has shared, then:

      • against the South African variant, 86 of 91 cases in South Africa with sequenced virus having the South African 20H/501Y.V2 variant, "vaccine efficacy against severe-critical COVID-19 was 7 52% and 64% against moderate to severe-critical COVID-19 with onset at least 14 days and at least 28days after administration respectively, and efficacy against severe-critical COVID-19 was 73.1% and 81,7% respectively."

      • while against the original variant, it was 66.9% (59-73.4) effective after 14 days and 85.4% (54.2-96.9) effective after 28 days.

      • So what I think this means that:

        • the J&J vaccine probably won't stop you catching (and probably transmitting) the South African variant of COVID

        • but it probably will stop you getting critically ill or dying from COVID.

        • And this probably suggests that this might also be true for AstraZeneca vaccine.   

​

​